DSpace at RU >

Browsing by Author Emery, P.

Full Text	Issue Date	Title	Author(s)
	2011	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010	Furst, D.E.; Keystone, E.C.; Braun, J.; Breedveld, F.C.; Burmester, G.R., et al
	2010	Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions.	Davidovici, B.B.; Sattar, N.; Prinz, J.C.; Puig, L.; Emery, P., et al
	2010	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.	Smolen, J.S.; Landewe, R.; Breedveld, F.C.; Dougados, M.; Emery, P., et al
	2010	Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci.	Stahl, E.A.; Raychaudhuri, S.; Remmers, E.F.; Xie, G.; Eyre, S., et al
	2010	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.	Furst, D.E.; Keystone, E.C.; Fleischmann, R.; Mease, P.; Breedveld, F.C., et al
	2009	Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe.	Emery, P.; Vollenhoven, R. van; Ostergaard, M.; Choy, E.; Combe, B., et al
	2008	Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis.	Karonitsch, T.; Aletaha, D.; Boers, M.; Bombardieri, S.; Combe, B., et al
	2008	Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.	Aletaha, D.; Landewe, R.B.; Karonitsch, T.; Bathon, J.; Boers, M., et al
	2008	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008	Furst, D.E.; Keystone, E.C.; Kirkham, B.; Kavanaugh, A.; Fleischmann, R., et al
	2008	Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.	Aletaha, D.; Landewe, R.B.; Karonitsch, T.; Bathon, J.; Boers, M., et al
	2007	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.	Furst, D.E.; Breedveld, F.C.; Kalden, J.R.; Smolen, J.S.; Burmester, G.R., et al
	2006	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.	Furst, D.E.; Breedveld, F.C.; Kalden, J.R.; Smolen, J.S.; Burmester, G.R., et al
	2005	When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?	Dougados, M.; Emery, P.; Lemmel, E.M.; Zerbini, C.A.; Brin, S., et al
	2005	Minimal disease activity for rheumatoid arthritis: a preliminary definition.	Wells, G.A.; Boers, M.; Shea, B.; Brooks, P.M.; Simon, L.S., et al
	2005	Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis.	Kalden, J.R.; Antoni, C.; Alvaro-Gracia, J.M.; Combe, B.; Emery, P., et al
	2004	Leflunomide : a manageable safety profile	Riel, P.L.C.M. van; Smolen, J.S.; Emery, P.; Kalden, J.R.; Dougados, M., et al
	2004	The efficacy of leflunomide monotherapy in rheumatoid arthritis : towards the goals of disease modifying antirheumatic drug therapy	Smolen, J.S.; Emery, P.; Kalden, J.R.; Riel, P.L.C.M. van; Dougados, M., et al
	2004	Lefunomide in combination therapy	Kalden, J.R.; Smolen, J.S.; Emery, P.; Riel, P.L.C.M. van; Dougados, M., et al
	2004	Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry.	Farge, D.; Passweg, J.R.; Laar, J.M. van; Marjanovic, Z.; Besenthal, C., et al
	1996	New perspectives on controlling progression of severe rheumatoid arthritis - a summary of the potential role of cyclosporin	Emery, P.; Putte, L.B.A. van de